Trial Profile

A Phase 4 Double-blinded, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sugammadex (Primary) ; Atropine; Glycopyrrolate; Glycopyrrolate/neostigmine; Neostigmine; Neostigmine/atropine
Indications Neuromuscular blockade
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Merck Sharp & Dohme Corp.

29 Sep 2023 Status changed from recruiting to completed.
06 Jul 2023 Planned End Date changed from 31 Aug 2023 to 29 Feb 2024.
06 Jul 2023 Planned primary completion date changed from 31 Aug 2023 to 29 Feb 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com